The clinicopathological significance and prognosis of long non-coding RNA SNHG14 expression in human cancers: a meta-analysis

Abstract

Abstract Background Recently, the role of long non-coding RNA small nucleolar host gene14 (SNHG14) in various human cancers has attracted much attention. We will investigate the effects of SNHG14 expression on clinicopathological features and prognosis of different types of human cancer patients by meta-analysis. Methods We had speculated the potential association between SNHG14 expression and the prognostic significance and clinical features of cancer patients during some studies were searched electronically using PubMed, EMBASE and Cochrane Library. Cochrane collaboration software (RevMan 5.3) was used to analyze the potential association between SNHG14 expression and prognostic significance and clinical features of cancer patients. Fixed and random-effects were used to measure pooled estimates. Corresponding odds ratios (OR) OR risk ratios (HR) and their 95% confidence intervals (CI) were compared to evaluate the prognostic value of SNHG14. Result Overall, 19 randomized controlled trials were included in this meta-analysis, with a total of 1221 patients. The high expression rate of SNHG14 in the TNM stage I-II group was lower than that in the stage III-IV group (OR = 0.63; 95% CI,0.45 ~ 0.88; P = 0.006). In terms of lymph node metastasis, the high expression rate of SNHG14 in the group without lymph node metastasis was significantly lower than that in the group with lymph node metastasis (OR = 0.47; 95%CI, 0.33 ~ 0.65, P＜0.00001); As for distant metastasis, the high expression rate of SNHG14 in the group without distant metastasis was lower than that in the group with distant metastasis (OR = 0.41; 95%CI, 0.20 ~ 0.83;P = 0.01). In terms of survival outcome, high SNHG14 expression was significantly associated with poor OS (HR = 1.56; 95%CI, 1.22 ~ 1.99, P = 0.0004). Conclusion High expression of LncRNA SNHG14 is significantly associated with poor prognosis and advanced clinical features, suggesting that LncRNA SNHG14 can be used as a potential biomarker for predicting prognosis and clinical features in patients with various cancers.